Wednesday, November 13, 2013 6:27:44 PM
He has been here since the beginning:) Nah,That info is hard to come by.The news is always he owns owns owns it.Not much news about his recent sell on OCT 8 per form 144(look at OPK filings)
SOUNDS like BZNE is cooking up a private BIO company purchase backed by the latest PUMP and DUMP here IMO..Rinse Repeat?
Looks like they CHEAPLY dumped the recently highly spoken assets to obtain some new ones.lol
DR FRost:)
SOUNDS like BZNE is cooking up a private BIO company purchase backed by the latest PUMP and DUMP here IMO..Rinse Repeat?
Looks like they CHEAPLY dumped the recently highly spoken assets to obtain some new ones.lol
DR FRost:)
MY Opinion
Recent COCP News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/26/2026 12:30:22 PM
- Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza • GlobeNewswire Inc. • 05/26/2026 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 12:30:34 PM
- Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results • GlobeNewswire Inc. • 05/15/2026 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/04/2026 04:15:12 AM
- Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection • GlobeNewswire Inc. • 04/30/2026 08:05:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 04/23/2026 09:00:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:30:27 PM
- Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive • GlobeNewswire Inc. • 04/02/2026 12:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2026 12:30:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 12:30:22 PM
- Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs • GlobeNewswire Inc. • 03/31/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2026 08:30:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/09/2026 12:30:32 PM
- First Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment • GlobeNewswire Inc. • 03/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/19/2026 01:30:54 PM
- Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026 • GlobeNewswire Inc. • 02/19/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 09:10:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:10:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:10:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:10:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2025 02:00:25 PM
- Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus • GlobeNewswire Inc. • 12/18/2025 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2025 09:30:29 PM
- Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference • GlobeNewswire Inc. • 12/01/2025 01:00:00 PM
